In Silico and In Vitro Perspectives on the Potential Anticancer Activity and Toxicity of Anticancer Drug Modified with Carbohydrates Containing Novel Triazole Compounds

Basit Öğe Kaydı
dc.contributor.authorGokmen, Buse
dc.contributor.authorGuler, Cem
dc.contributor.authorSanci, Ebru
dc.contributor.authorDemir, Ramiz
dc.contributor.authorKarayildirim, Cinel Koksal
dc.contributor.authorAlsakini, Karrar Ali Mohammed Hasan
dc.contributor.authorNalbantsoy, Ayse
dc.date.accessioned2026-04-25T14:19:44Z
dc.date.available2026-04-25T14:19:44Z
dc.date.issued2025
dc.departmentSinop Üniversitesi
dc.description.abstract5-Fluorouracil (5-FU) is one of the first-line chemotherapeutic agents used in systemic therapy of solid tumors. However, several challenges restrict the use of 5-FU such as serious side effects and short plasma half-life. Because carbohydrates and 1,2,3-triazoles have various biological activities, they have been extensively used in medicine to obtain more effective anticancer drugs in recent years. The aim of this study is to modify 5-FU with carbohydrates containing 1,2,3-triazole compounds to reduce its toxic effect, and to reveal the anticancer properties of the obtained 5-FU derivatives. These derivatives (5-FU-I, 5-FU-II, and 5-FU-III) revealed dose-dependent cytotoxic effects on CaCo-2, PANC-1, and A549 cancer cells. It was determined that cytotoxic effects of the 5-FUs change dependent on used carbohydrate types, cell lines, and administered doses. These derivatives showed apoptotic and necrotic cell deaths which used to destroy the cancer cells. 5-FUs showed no genotoxic effect in the bacterial reverse mutasyon assay. They demonstrated strong antiangiogenic properties in the HET-CAM test. In silico study results demonstrated that carbohydrate modification can increase half-life and clearance, also decrease side effects of 5-FU. In silico data supported the in vitro findings and results demonstrated 5-FU derivatives were better drug candidates. Our results reveal that 5-FUs derivatives modified carbohydrates containing 1,2,3-triazole compounds have potential in cancer therapy.
dc.description.sponsorshipEge University Research Foundation [FYL-2021-23138]; Ege University, Scientific Research Foundation
dc.description.sponsorshipB.G. and C.G. contributed equally. This study was supported by Ege University, Scientific Research Foundation (Project number is FYL-2021-23138).
dc.identifier.doi10.1002/slct.202405927
dc.identifier.issn2365-6549
dc.identifier.issue21
dc.identifier.orcid0000-0001-6435-7883
dc.identifier.orcid0000-0003-3295-3538
dc.identifier.orcid0000-0003-4945-4794
dc.identifier.scopus2-s2.0-105006719380
dc.identifier.scopusqualityN/A
dc.identifier.urihttps://doi.org/10.1002/slct.202405927
dc.identifier.urihttps://hdl.handle.net/11486/8142
dc.identifier.volume10
dc.identifier.wosWOS:001497171700001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherWiley-V C H Verlag Gmbh
dc.relation.ispartofChemistryselect
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20260420
dc.subject1,2,3-triazole compounds
dc.subject5-Fluorouracil
dc.subjectAntiangiogenic activity
dc.subjectApoptosis
dc.subjectIn silico
dc.subjectIn vitro
dc.subjectToxicity
dc.titleIn Silico and In Vitro Perspectives on the Potential Anticancer Activity and Toxicity of Anticancer Drug Modified with Carbohydrates Containing Novel Triazole Compounds
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu